PDB Short entry for 1QD8 HEADER ANTIBIOTIC 15-JUL-99 1QD8 TITLE COMPLEX OF VANCOMYCIN WITH N-ACETYL GLYCINE CAVEAT 1QD8 BGC D 1 HAS WRONG CHIRALITY AT ATOM C5 COMPND MOL_ID: 1; COMPND 2 MOLECULE: VANCOMYCIN; COMPND 3 CHAIN: A, B; COMPND 4 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: AMYCOLATOPSIS ORIENTALIS; SOURCE 3 ORGANISM_TAXID: 31958 KEYWDS GLYCOPEPTIDE, ANTIBIOTIC EXPDTA X-RAY DIFFRACTION AUTHOR P.J.LOLL,J.KAPLAN,B.SELINSKY,P.H.AXELSEN REVDAT 10 27-DEC-23 1QD8 1 HETSYN LINK REVDAT 9 29-JUL-20 1QD8 1 CAVEAT COMPND REMARK SEQRES REVDAT 9 2 1 HETNAM LINK SITE ATOM REVDAT 8 27-JUL-11 1QD8 1 REMARK REVDAT 7 13-JUL-11 1QD8 1 VERSN REVDAT 6 24-FEB-09 1QD8 1 VERSN REVDAT 5 01-APR-03 1QD8 1 JRNL REVDAT 4 27-DEC-00 1QD8 1 REMARK REVDAT 3 23-DEC-99 1QD8 1 JRNL HEADER REVDAT 2 23-AUG-99 1QD8 1 COMPND SOURCE REVDAT 1 16-AUG-99 1QD8 0 JRNL AUTH P.J.LOLL,J.KAPLAN,B.S.SELINSKY,P.H.AXELSEN JRNL TITL VANCOMYCIN BINDING TO LOW-AFFINITY LIGANDS: DELINEATING A JRNL TITL 2 MINIMUM SET OF INTERACTIONS NECESSARY FOR HIGH-AFFINITY JRNL TITL 3 BINDING. JRNL REF J.MED.CHEM. V. 42 4714 1999 JRNL REFN ISSN 0022-2623 JRNL PMID 10579833 JRNL DOI 10.1021/JM990361T REMARK 2 REMARK 2 RESOLUTION. 1.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 95.6 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.110 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.131 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 975 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 14823 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE (F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 160 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 53 REMARK 3 SOLVENT ATOMS : 40 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : NULL REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : NULL REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : NULL REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : NULL REMARK 3 NUMBER OF RESTRAINTS : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.017 REMARK 3 ANGLE DISTANCES (A) : NULL REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : NULL REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : NULL REMARK 3 ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : NULL REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : NULL REMARK 3 SIMILAR ADP COMPONENTS (A**2) : NULL REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT WAS CARRIED OUT AGAINST F REMARK 3 -SQUARED USING SHELXL-93. MOLECULAR GEOMETRY AND ATOMIC REMARK 3 DISPLACEMENT PARAMETERS WERE RESTRAINED THROUGHOUT. INDEPENDENT REMARK 3 VANCOMYCIN MONOMERS WERE RESTRAINED TO HAVE SIMILAR 1-2 AND 1-3 REMARK 3 DISTANCES; RESTRAINTS WERE ALSO IMPOSED TO LIMIT DEVIATIONS FROM REMARK 3 PLANARITY IN RINGS AND SP2 SYSTEMS. ALONG-BOND COMPONENTS OF REMARK 3 ANISOTROPIC DISPLACEMENT PARAMETERS WERE SUBJECTED TO REMARK 3 RESTRAINTS. SOLVENT WATER ATOMS WERE RESTRAINED TO BE REMARK 3 APPROXIMATELY ISOTROPIC AND WERE MADE SUBJECT TO ANTI-BUMPING REMARK 3 RESTRAINTS. CONJUGATE GRADIENT REFINEMENT WAS USED THROUGHOUT, REMARK 3 EXCEPT AT THE LAST STAGES, WHEN BLOCKED LEAST SQUARES WAS USED. REMARK 4 REMARK 4 1QD8 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-JUL-99. REMARK 100 THE DEPOSITION ID IS D_1000001223. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-SEP-96 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : CHESS REMARK 200 BEAMLINE : A1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.918 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : CUSTOM-MADE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 14172 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.000 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.0 REMARK 200 DATA REDUNDANCY : 23.40 REMARK 200 R MERGE (I) : 0.04200 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 46.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.04 REMARK 200 COMPLETENESS FOR SHELL (%) : 62.0 REMARK 200 DATA REDUNDANCY IN SHELL : 2098. REMARK 200 R MERGE FOR SHELL (I) : 0.06500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: SHELXL-93 REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 58.88 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.99 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SODIUM CHLORIDE, N-ACETYL GLYCINE, PH REMARK 280 4.6, VAPOR DIFFUSION/HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 43 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+3/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+1/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+3/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+1/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 33.38500 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 14.35500 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 14.35500 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 50.07750 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 14.35500 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 14.35500 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 16.69250 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 14.35500 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 14.35500 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 50.07750 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 14.35500 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 14.35500 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 16.69250 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 33.38500 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1670 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 2590 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -24.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, D REMARK 350 BIOMT1 2 0.000000 -1.000000 0.000000 14.35500 REMARK 350 BIOMT2 2 1.000000 0.000000 0.000000 14.35500 REMARK 350 BIOMT3 2 0.000000 0.000000 1.000000 -16.69250 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1940 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 2160 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 110 LIES ON A SPECIAL POSITION. REMARK 400 REMARK 400 COMPOUND REMARK 400 VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE. THE SCAFFOLD IS REMARK 400 A HEPTAPEPTIDE WITH THE CONFIGURATION D-D-L-D-D-L-L. IT IS REMARK 400 FURTHER GLYCOSYLATED BY A DISACCHARIDE MADE OF D-GLUCOSE REMARK 400 AND VANCOSAMINE. REMARK 400 HERE, VANCOMYCIN IS REPRESENTED BY GROUPING TOUGHER THE REMARK 400 SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) BGC AND RER. REMARK 400 REMARK 400 THE VANCOMYCIN IS GLYCOPEPTIDE, A MEMBER OF ANTIBIOTIC CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: VANCOMYCIN REMARK 400 CHAIN: A, B, C, D REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 COMPONENT_2: RESIDUE BGC REMARK 400 COMPONENT_3: RESIDUE RER REMARK 400 DESCRIPTION: VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED REMARK 400 BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O2 BGC D 1 O5 RER D 2 2.09 REMARK 500 C2 BGC D 1 C1 RER D 2 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 3 -69.02 -101.06 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AA5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN REMARK 900 RELATED ID: 1C0Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN COMPLEXED WITH 2-ACETOXY-D- REMARK 900 PROPANOIC ACID REMARK 900 RELATED ID: 1C0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN WITH D-LACTIC ACID REMARK 900 RELATED ID: 1FVM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN COMPLEXED WITH DI-ACETYL-LYS-D-ALA- REMARK 900 D-ALA REMARK 900 RELATED ID: 1GAC RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF A82846B COMPLEXED WITH ITS CELL WALL REMARK 900 PENTAPEPTIDE FRAGMENT REMARK 900 RELATED ID: 1GHG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN AGLYCON REMARK 900 RELATED ID: 1PN3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TDP-EPI-VANCOSAMINYLTRANSFERASE GTFA COMPLEXD REMARK 900 WITH TDP AND DESVANCOSAMINYL VANCOMYCIN REMARK 900 RELATED ID: 1PNV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TDP-EPI-VANCOSAMINYLTRANSFERASE GTFA COMPLEXED REMARK 900 WITH TDP AND VANCOMYCIN REMARK 900 RELATED ID: 1RRV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TDP-VANCOSAMINYLTRANSFERASE GTFD COMPLEXED REMARK 900 WITH TDP AND DESVANCOSAMINYL VANCOMYCIN. REMARK 900 RELATED ID: 1SHO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN DBREF 1QD8 A 1 7 NOR NOR00681 NOR00681 1 7 DBREF 1QD8 B 1 7 NOR NOR00681 NOR00681 1 7 SEQRES 1 A 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 B 7 MLU OMZ ASN GHP GHP OMY 3FG HET MLU A 1 9 HET OMZ A 2 14 HET GHP A 4 11 HET GHP A 5 11 HET OMY A 6 14 HET 3FG A 7 13 HET MLU B 1 9 HET OMZ B 2 14 HET GHP B 4 12 HET GHP B 5 11 HET OMY B 6 14 HET 3FG B 7 13 HET BGC C 1 11 HET RER C 2 10 HET BGC D 1 22 HET RER D 2 10 HET CL A 12 1 HET CL A 13 1 HET AAC B 11 8 HET CL B 12 1 HETNAM MLU N-METHYL-D-LEUCINE HETNAM OMZ (BETAR)-3-CHLORO-BETA-HYDROXY-D-TYROSINE HETNAM GHP (2R)-AMINO(4-HYDROXYPHENYL)ETHANOIC ACID HETNAM OMY (BETAR)-3-CHLORO-BETA-HYDROXY-L-TYROSINE HETNAM 3FG (2S)-AMINO(3,5-DIHYDROXYPHENYL)ETHANOIC ACID HETNAM BGC BETA-D-GLUCOPYRANOSE HETNAM RER VANCOSAMINE HETNAM CL CHLORIDE ION HETNAM AAC ACETYLAMINO-ACETIC ACID HETSYN BGC BETA-D-GLUCOSE; D-GLUCOSE; GLUCOSE HETSYN RER (1R,3S,4S,5S)-3-AMINO-2,3,6-TRIDEOXY-3-METHYL-ALPHA-L- HETSYN 2 RER ARABINO-HEXOPYRANOSE FORMUL 1 MLU 2(C7 H15 N O2) FORMUL 1 OMZ 2(C9 H10 CL N O4) FORMUL 1 GHP 4(C8 H9 N O3) FORMUL 1 OMY 2(C9 H10 CL N O4) FORMUL 1 3FG 2(C8 H9 N O4) FORMUL 3 BGC 2(C6 H12 O6) FORMUL 3 RER 2(C7 H15 N O3) FORMUL 5 CL 3(CL 1-) FORMUL 7 AAC C4 H7 N O3 FORMUL 9 HOH *40(H2 O) LINK C MLU A 1 N OMZ A 2 1555 1555 1.37 LINK C OMZ A 2 N ASN A 3 1555 1555 1.35 LINK OH OMZ A 2 C5 GHP A 4 1555 1555 1.41 LINK C ASN A 3 N GHP A 4 1555 1555 1.35 LINK C GHP A 4 N GHP A 5 1555 1555 1.36 LINK C3 GHP A 4 OCZ OMY A 6 1555 1555 1.42 LINK O4 GHP A 4 C1 BGC C 1 1555 1555 1.45 LINK C GHP A 5 N OMY A 6 1555 1555 1.35 LINK C3 GHP A 5 CG1 3FG A 7 1555 1555 1.50 LINK C OMY A 6 N 3FG A 7 1555 1555 1.37 LINK C MLU B 1 N OMZ B 2 1555 1555 1.35 LINK C OMZ B 2 N ASN B 3 1555 1555 1.34 LINK OH OMZ B 2 C5 GHP B 4 1555 1555 1.42 LINK C ASN B 3 N GHP B 4 1555 1555 1.36 LINK C GHP B 4 N GHP B 5 1555 1555 1.35 LINK C3 GHP B 4 OCZ OMY B 6 1555 1555 1.41 LINK O4 BGHP B 4 C1 BBGC D 1 1555 1555 1.45 LINK O4 AGHP B 4 C1 ABGC D 1 1555 1555 1.44 LINK C GHP B 5 N OMY B 6 1555 1555 1.36 LINK C3 GHP B 5 CG1 3FG B 7 1555 1555 1.48 LINK C OMY B 6 N 3FG B 7 1555 1555 1.35 LINK O2 BGC C 1 C1 RER C 2 1555 1555 1.45 LINK O2 BBGC D 1 C1 RER D 2 1555 1555 1.17 LINK O2 ABGC D 1 C1 RER D 2 1555 1555 1.50 CISPEP 1 GHP A 5 OMY A 6 0 6.84 CISPEP 2 GHP B 5 OMY B 6 0 19.89 CRYST1 28.710 28.710 66.770 90.00 90.00 90.00 P 43 21 2 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.034831 0.000000 0.000000 0.00000 SCALE2 0.000000 0.034831 0.000000 0.00000 SCALE3 0.000000 0.000000 0.014977 0.00000 HETATM 1 N MLU A 1 10.194 8.907 -4.114 1.00 5.65 N HETATM 2 CN MLU A 1 10.547 10.252 -4.701 1.00 8.07 C HETATM 3 CA MLU A 1 8.943 8.890 -3.314 1.00 4.90 C HETATM 4 C MLU A 1 7.787 9.331 -4.237 1.00 4.52 C HETATM 5 O MLU A 1 7.591 8.754 -5.316 1.00 6.61 O HETATM 6 CB MLU A 1 8.636 7.500 -2.759 1.00 5.64 C HETATM 7 CG MLU A 1 9.690 6.851 -1.805 1.00 5.74 C HETATM 8 CD1 MLU A 1 9.918 7.652 -0.594 1.00 10.12 C HETATM 9 CD2 MLU A 1 9.196 5.485 -1.382 1.00 9.15 C HETATM 10 N OMZ A 2 6.952 10.319 -3.792 1.00 3.84 N HETATM 11 CA OMZ A 2 5.873 10.834 -4.630 1.00 3.99 C HETATM 12 C OMZ A 2 4.528 10.069 -4.508 1.00 3.91 C HETATM 13 O OMZ A 2 3.555 10.382 -5.247 1.00 4.48 O HETATM 14 CB OMZ A 2 5.573 12.372 -4.436 1.00 4.37 C HETATM 15 OC OMZ A 2 6.789 13.131 -4.559 1.00 4.90 O HETATM 16 CG OMZ A 2 4.894 12.657 -3.108 1.00 4.23 C HETATM 17 CD1 OMZ A 2 3.533 12.862 -3.077 1.00 4.82 C HETATM 18 CD2 OMZ A 2 5.625 12.679 -1.894 1.00 4.55 C HETATM 19 CE1 OMZ A 2 2.830 13.035 -1.860 1.00 5.18 C HETATM 20 CL OMZ A 2 1.128 13.336 -1.859 1.00 8.37 CL HETATM 21 CE2 OMZ A 2 4.936 12.830 -0.686 1.00 4.97 C HETATM 22 CZ OMZ A 2 3.552 12.977 -0.681 1.00 4.89 C HETATM 23 OH OMZ A 2 2.862 13.033 0.571 1.00 5.72 O